The Pharma Data

OCTOBER 21, 2020

21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

DECEMBER 8, 2020

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. Laying down a new track for RNA processing, Remix launched with $81 million in financing. Pear Therapeutics.

RNA 52

RNA Therapies Disease Protein Expression 52

Molecule Blog

MARCH 17, 2023

The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering 52

Engineering Research Clinical Trials Government 52

Metabolite Tales Blog

JANUARY 26, 2023

Table 1 – Small molecule drugs approved by the FDA in 2022 and the major reported route of biotransformation *Note: 17 small molecule drugs as classified in C&EN ( [link] i.e. excluding antibody-drug conjugates, antibodies, proteins, radioligands and small interfering RNA).

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

The Pharma Data

OCTOBER 27, 2020

Under the agreement, during the option period, Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials, with Molecular Partners as sponsor of these trials.

Therapies 40

Therapies Virus Treatment Clinical Trials 40

Codon

MARCH 24, 2024

Water accounts for 70 percent of a bacterium by mass; the other 30 percent includes everything else: proteins, RNA, DNA, lipids, and so on. And given that RNA and lipid nanoparticle synthesis is highly efficient compared to typical bioproduction, it’s likely that the company could have scaled to billions of doses.

Engineering 86

Engineering Vaccine Production RNA 86

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52